REFRACTORY COLORECTAL ADENOCARCINOMA
Clinical trials for REFRACTORY COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat colorectal cancer? early trial combines three drugs
Disease control TerminatedThis early-phase study tests whether adding a new drug (ZEN003694) to two approved cancer drugs (cetuximab and encorafenib) is safe and effective for people with a specific type of advanced colorectal cancer (BRAF V600E) that has stopped responding to standard treatments. About 3…
Matched conditions: REFRACTORY COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
New hope for tough colorectal cancer: drug combo trial targets resistant tumors
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. About 59 participants will receive either panitumumab…
Matched conditions: REFRACTORY COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC